220720 AVCN NR Image
Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals
20 juil. 2022 07h30 HE | Avicanna Inc.
Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform TORONTO, July 20, 2022 (GLOBE...
Avicanna.png
Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders
11 juil. 2022 17h15 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
220707 AVCN NR Image
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union
07 juil. 2022 07h30 HE | Avicanna Inc.
The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio Initial portfolio launch is planned for Germany, Austria, and...
Avicanna.png
Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa
24 juin 2022 07h30 HE | Avicanna Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
220609 AVCN NR Image
Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho
09 juin 2022 07h30 HE | Avicanna Inc.
This export marks the 16th international market entry for Avicanna and the first export of proprietary genetics into Africa. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR...
220524 AVCN NR Image
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureus™ Branded THC and CBD Extracts to Portugal
24 mai 2022 07h30 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, May 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:...
Avicanna.png
Avicanna Reports Q1 2022 Financial Statement and Management Change
12 mai 2022 21h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna.png
Avicanna Announces Closing of Strategic Private Placement
06 mai 2022 17h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna.png
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market
28 avr. 2022 07h30 HE | Avicanna Inc.
Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations RHO Phyto CBG products will be made available through...
Avicanna.png
Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company
13 avr. 2022 07h00 HE | Avicanna Inc.
TORONTO, April 13, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development and...